Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 10/20 | 0.62 |
| ▸ | DDR2 | Q16832 | 5/20 | 0.62 |
| ▸ | LCK | P06239 | 4/20 | 0.62 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.62 |
| ▸ | DDR1 | Q08345 | 4/20 | 0.62 |
| ▸ | SRC | P12931 | 3/20 | 0.62 |
| ▸ | EPHB2 | P29323 | 3/20 | 0.62 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.62 |
| ▸ | ESYT2 | A0FGR8 | 2/20 | 0.62 |
| ▸ | NBAS | A2RRP1 | 2/20 | 0.62 |
| ▸ | CNOT1 | A5YKK6 | 2/20 | 0.62 |
| ▸ | TBKBP1 | A7MCY6 | 2/20 | 0.62 |
| ▸ | AGPS | O00116 | 2/20 | 0.62 |
| ▸ | MYO1F | O00160 | 2/20 | 0.62 |
| ▸ | SNAP23 | O00161 | 2/20 | 0.62 |
| ▸ | AP3B1 | O00203 | 2/20 | 0.62 |
| ▸ | PSMD12 | O00232 | 2/20 | 0.62 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.62 |
| ▸ | PGRMC1 | O00264 | 2/20 | 0.62 |
| ▸ | CLIC1 | O00299 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4919390 | 0.95 | BRAF (0.61) | BRAFDDR2LCKMAPK14DDR1 | |
| SCHEMBL4698022 | 0.91 | BRAF (0.59) | BRAFDDR2LCKMAPK14DDR1 | |
| SCHEMBL4699844 | 0.88 | POLB (0.61) | BRAFDDR2LCKMAPK14DDR1 | |
| SCHEMBL4699947 | 0.87 | ABL1 (0.83) | BRAFDDR2LCKMAPK14DDR1 | |
| SCHEMBL20558364 | 0.82 | BRAF (0.64) | BRAFDDR2LCKMAPK14DDR1 | |
| SCHEMBL4787068 | 0.81 | BRAF (0.57) | BRAFABL1LMNABTKKDR | |
| SCHEMBL4915098 | 0.81 | BRAF (0.73) | BRAFDDR2LCKMAPK14DDR1 | |
| SCHEMBL22025316 | 0.80 | BRAF (0.80) | BRAFDDR2LCKMAPK14DDR1 | |
| SCHEMBL4696313 | 0.80 | POLB (0.59) | BRAFDDR2LCKMAPK14DDR1 | |
| SCHEMBL4908396 | 0.80 | BRAF (0.74) | BRAFDDR2LCKMAPK14DDR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275054-A1 | 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors | HOLZER PHILIPP | 2008-11-06 | — | — | US | claimed |
| EP-1963327-A1 | 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS | Novartis AG (CH) | 2008-09-03 | — | — | EP | claimed |
| WO-2007062805-A1 | 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-06-07 | — | — | WO | claimed |
| US-20080275054-A1 | 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors | HOLZER PHILIPP | 2008-11-06 | — | — | US | disclosed |
| EP-1963327-A1 | 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007062805-A1 | 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275054-A1 | 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors | EPHB3, EPHB2, EPHB1 | BRAF 42/4885DDR2 632/4885LCK 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.